TrialSignal transduction and targeted therapy2026

Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study.

Xiaoyun Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.